Imaging breast cancer response during neoadjuvant systemic therapy

References

• Hortobagyi GN, Ames FC, Buzdar AU et al. Management of Stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62, 2507–2516 (1988).
   PubMed Web of Science ®Google Scholar
• Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 43(4), 1488–1492 (1983).
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Poisson R et al. Eight-year results of a randomised clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med. 320, 822–828 (1989).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Zucali R, Luini A. Local control and survival in early breast cancer: the Milan trial. Int. J. Radiat. Oncol. Biol. Phys. 12(5), 717–720 (1986).
   PubMed Web of Science ®Google Scholar
• Makris A, Powles TJ, Ahsley SE et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann. Oncol. 9(11), 1179–1184 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15(7), 2483–2493 (1997).
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16(8), 2672–2685 (1998).
   PubMed Web of Science ®Google Scholar
• Ellis P, Smith I, Ashley S et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol. 16, 107–114 (1998).
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J. Clin. Oncol. 16, 93–100 (1998).
   PubMed Web of Science ®Google Scholar
• Machiavelli MR, Romero A, Perez JE et al. Prognostic significance of pathological response of primary tumour and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J. Sci. Am. 4(2), 125–131 (1998).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project. J. Natl Cancer Inst. Monogr. 30, 96–102 (2001).
   PubMedGoogle Scholar
• Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann. Oncol. 16(2), 267–272 (2005).
   PubMedGoogle Scholar
• Kennedy S, Merino MJ, Swain SM, Lippman ME. The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. Hum. Pathol. 21(2), 192–198 (1990).
   PubMedGoogle Scholar
• Ferrozzi F, Tognini G, Pavone P. Structural changes induced by antineoplastic therapies: keys to evaluate tumor response to treatment. Eur. Radiol. 12(4), 928–937 (2002).
   PubMedGoogle Scholar
• Sharkey FE, Addington SL, Fowler LJ, Page CP, Cruz AB. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod. Pathol. 9(9), 893–900 (1996).
   PubMedGoogle Scholar
• Moll UM, Chumas J. Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer. Pathol. Res. Pract. 193(3), 187–196 (1997).
   PubMedGoogle Scholar
• Honkoop AH, Pinedo HM, De Jong JS et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am. J. Clin. Pathol. 107(2), 211–218 (1997).
   PubMedGoogle Scholar
• Smith IC, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 12(Suppl. 1), S25–S29 (2001).
   Google Scholar
• Kuerer HM, Newman LA, Buzdar AU et al. Pathologic tumour response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J. Sci. Am. 4, 230–236 (1998).
   PubMedGoogle Scholar
• Ogston KN, Miller ID, Payne S et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12, 320–327 (2003).
   PubMed Web of Science ®Google Scholar
• Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 46(5), 2578–2581 (1986).
   PubMed Web of Science ®Google Scholar
• Bottini A, Berruti A, Tampellini M et al. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15–3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Tumour Biol. 18(5), 301–310 (1997).
   Google Scholar
• Berberoglu U, Yildirim E, Celen O. Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int. J. Biol. Markers 19(2), 130–134 (2004).
   PubMed Web of Science ®Google Scholar
• Moskovic EC, Mansi JL, King DM, Murch CR, Smith IE. Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin. Radiol. 47(5), 339–344 (1993).
   PubMed Web of Science ®Google Scholar
• Cocconi G, Di Blasio B, Alberti G, Bisagni G, Botti E, Peracchia G. Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res. Treat. 4(4), 309–313 (1984).
   PubMedGoogle Scholar
• Segel MC, Paulus DD, Hortobagyi GN. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 169(1), 49–54 (1988).
   PubMedGoogle Scholar
• Vinnicombe SJ, MacVicar AD, Guy RL et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198(2), 333–340 (1996).
   PubMedGoogle Scholar
• Helvie MA, Joynt LK, Cody RL, Pierce LJ, Adler DD, Merajver SD. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 198(2), 327–332 (1996).
   PubMed Web of Science ®Google Scholar
• Skaane P, Skjennald A. Screen-film mammography versus full-field digital mammography with soft-copy reading: randomized trial in a population-based screening program – the Oslo II Study. Radiology 232(1), 197–204 (2004).
   PubMedGoogle Scholar
• Lewin JM, D’Orsi CJ, Hendrick RE et al. Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. AJR Am. J. Roentgenol. 179(3), 671–677 (2002).
   PubMedGoogle Scholar
• Yang W, Lam WW, Cheung H, Suen M, King WW, Metreweli C. Sonographic, magnetic resonance imaging and mammographic assessments of preoperative size of breast cancer. J. Ultrasound Med. 16, 791–797 (1997).
   PubMed Web of Science ®Google Scholar
• Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin. Cancer Res. 3(9), 1565–1569 (1997).
   PubMed Web of Science ®Google Scholar
• Burcombe R, Wilson GD, Richman PI et al. Comparison of clinical, radiological and pathological assessment of response to neoadjuvant chemotherapy for primary breast cancer. European Cancer Conference, Lisbon, Portugal (2001).
   Google Scholar
• Fiorentino C, Berruti A, Bottini A et al. Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res. Treat. 69(2), 143–151 (2001).
   PubMedGoogle Scholar
• Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC. Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging. Radiology 190(3), 825–830 (1994).
   PubMedGoogle Scholar
• Moyses B, Haegele P, Rodier JF et al. Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer. Clin. Breast Cancer 2(4), 304–310 (2002).
   PubMedGoogle Scholar
• Akashi-Tanaka S, Fukutomi T, Watanabe T et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int. J. Cancer 96(1), 66–73 (2001).
   PubMedGoogle Scholar
• Akashi-Tanaka S, Fukutomi T, Sato N et al. The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. Ann. Surg. 239(2), 238–243 (2004).
   PubMedGoogle Scholar
• Miles KA. Functional CT imaging in oncology. Eur. Radiol. 13(Suppl. 5), M134–M138 (2003).
   Google Scholar
• Sahani DV, Kalva SP, Hamberg LM et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 234(3), 785–792 (2005).
   PubMed Web of Science ®Google Scholar
• Khalkhali I, Baum JK, Villanueva-Meyer J et al. Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results. J. Nucl. Med. 41(12), 1973–1979 (2000).
   PubMed Web of Science ®Google Scholar
• Cayre A, Cachin F, Maublant J et al. Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. Int. J. Oncol. 20(5), 1049–1055 (2002).
   PubMedGoogle Scholar
• Tiling R, Kessler M, Untch M et al. Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography. Onkologie 26, 27–31 (2003).
   PubMedGoogle Scholar
• Esserman L, Hylton N, Yassa L et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J. Clin. Oncol. 17(1), 110–119 (1999).
   PubMed Web of Science ®Google Scholar
• Abraham DC, Jones RC, Jones SE et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78(1), 91–100 (1996).
   PubMed Web of Science ®Google Scholar
• Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kuhn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur. Radiol. 12(7), 1711–1719 (2002).
   PubMed Web of Science ®Google Scholar
• Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am. J. Roentgenol. 179(5), 1193–1199 (2002).
   PubMed Web of Science ®Google Scholar
• Warren RM, Bobrow LG, Earl HM et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy. Br. J. Cancer 90, 1349–1360 (2004).
   PubMedGoogle Scholar
• Padhani AR, Dzik-Jurasz A. Perfusion MR imaging of extracranial tumour angiogenesis. Top. Magn. Reson. Imaging 15(1), 41–57 (2004).
   PubMedGoogle Scholar
• Ah-See ML, Padhani AR. Dynamic magnetic resonance imaging in breast cancer. In: Dynamic Contrast-enhanced Magnetic Resonance Imaging in Oncology. Jackson A, Parker GJM (Eds). Springer-Verlag, Berlin, Germany, 145–174 (2004).
   Google Scholar
• Knopp MV, Brix G, Junkermann HJ, Sinn HP. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn. Reson. Imaging Clin. N. Am. 2(4), 633–658 (1994).
   PubMedGoogle Scholar
• Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 15(2), 154–163 (2002).
   PubMed Web of Science ®Google Scholar
• Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology 228(1), 63–69 (2003).
   PubMed Web of Science ®Google Scholar
• Drew PJ, Kerin MJ, Mahapatra T et al. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur. J. Surg. Oncol. 27(7), 617–620 (2001).
   PubMed Web of Science ®Google Scholar
• Martincich L, Montemurro F, De Rosa G et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res. Treat. 83(1), 67–76 (2004).
   PubMed Web of Science ®Google Scholar
• Padhani AR. Contrast-enhanced MRI to predict clinico-pathological response of breast cancer to primary chemotherapy. Initial clinical results. Mount Vernon Hospital (Middlesex, UK) (2005).
   Google Scholar
• Ah-See ML, Makris A, Taylor NJ et al. Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer? In: American Society of Clinical Oncology. LA, USA (2004).
   Google Scholar
• Leach MO, Verrill M, Glaholm J et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed. 11(7), 314–340 (1998).
   PubMedGoogle Scholar
• Redmond OM, Stack JP, O’Connor et al. 31P MRS as an early prognostic indicator of patient response to chemotherapy. Magn. Reson. Med. 25(1), 30–44 (1992).
   PubMedGoogle Scholar
• Gribbestad IS, Singstad TE, Nilsen G et al. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J. Magn. Reson. Imaging 8(6), 1191–1197 (1998).
   PubMedGoogle Scholar
• Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl Cancer Inst. 94(16), 1197–1203 (2002).
   PubMedGoogle Scholar
• Jagannathan NR, Kumar M, Seenu V et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer 84(8), 1016–1022 (2001).
   PubMedGoogle Scholar
• Meisamy S, Bolan PJ, Baker EH et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy – a pilot study at 4 T. Radiology 233(2), 424–431 (2004).
   PubMed Web of Science ®Google Scholar
• Williams K, Williams F, Handley R. Infra-red thermometry in the diagnosis of breast disease. Lancet 2, 1378–1381 (1961).
   PubMedGoogle Scholar
• Chance B, Nioka S, Zhang J et al. Breast cancer detection based on incremental biochemical and physiological properties of breast cancers a six-year, two-site study. Acad. Radiol. 12(8), 925–933 (2005).
   PubMedGoogle Scholar
• Godavarty A, Thompson AB, Roy A et al. Diagnostic imaging of breast cancer using fluorescence-enhanced optical tomography: phantom studies. J. Biomed. Opt. 9(3), 488–496 (2004).
   PubMed Web of Science ®Google Scholar
• Hawrysz DJ, Sevick-Muraca EM. Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. Neoplasia 2(5), 388–417 (2000).
   PubMed Web of Science ®Google Scholar
• Jakubowski DB, Cerussi AE, Bevilacqua F et al. Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study. J. Biomed. Opt. 9(1), 230–238 (2004).
   PubMedGoogle Scholar
• Wahl R, Cody R, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radio-labeled glucose analogue 2–[F-18]-fluoro-D-glucose. Radiology 179, 765–770 (1991).
   PubMed Web of Science ®Google Scholar
• Adler L, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2–deoxy-2-fluoro-D-glucose PET. Radiology 187, 743–750 (1993).
   PubMed Web of Science ®Google Scholar
• Bassa P, Kim EE, Inoue T et al. Evaluation of preoperative chemotherapy using PET with Fluorine-18-fluorodeoxyglucose in breast cancer. J. Nucl. Med. 37, 931–938 (1996).
   PubMed Web of Science ®Google Scholar
• Wahl R, Zasadny K, Helvie M. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J. Clin. Oncol. 11, 2101–2111 (1993).
   PubMed Web of Science ®Google Scholar
• Jansson T, Westlin J, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early evaluation? J. Clin. Oncol. 13, 1470–1477 (1995).
   PubMedGoogle Scholar
• Schelling M, Avril N, Nahrig J et al. Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol. 18, 1689–1695 (2000).
   PubMed Web of Science ®Google Scholar
• Smith IC, Welch AE, Hutcheon AW et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J. Clin. Oncol. 18(8), 1676–1688 (2000).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim SK, Lee ES, Ro J, Kang S. Predictive value of [18F]FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy. Ann. Oncol. 15, 1352–1357 (2004).
   PubMedGoogle Scholar
• Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur. J. Cancer 38(3), 375–379 (2002).
   PubMedGoogle Scholar
• Shields A, Grierson JR, Dohman BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med. 4, 1334–1336 (1998).
   PubMed Web of Science ®Google Scholar
• Shields AF, Mankoff DA, Link JM et al. Carbon-11-thymidine and FDG to measure therapy response. J. Nucl. Med. 39(10), 1757–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Vesselle H, Grierson J, Muzi M et al. In vivo vaidation of 3'deoxy-3'-[18F]fluorothymidine as a proliferation imaging tracer in humans: correlation of FLT uptake by positron emission tomography with Ki67 immunohistochemistry and flow cytometry in human lung tissue. Clin. Cancer Res. 8, 3315–3323 (2002).
   PubMed Web of Science ®Google Scholar
• Dittman H, Dohmen BM, Paulsen F et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur. J. Nuc. Med. Mol. Imaging 30(10), 1407–1412 (2003).
   PubMedGoogle Scholar
• Smyczek-Gargya B, Fersis N, Dittmann H et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur. J. Nuc. Med. Mol. Imaging 31(5), 720–724 (2004).
   PubMed Web of Science ®Google Scholar
• Buck AK, Halter G, Schirrmeister H. Imaging proliferation in lung tumours with PET: 18F-FLT versus 18F-FDG. J. Nucl. Med. 44, 1426–1431 (2003).
   PubMed Web of Science ®Google Scholar
• Pio B, Park C, Satyamurthy N et al. Monitoring early and long-term effects of breast cancer chemotherapy with fluorodeoxyglucose and fluoro-L-thymidine. In: Society of Nuclear Medicine 50th Annual Meeting 2004. New Orleans, LA, USA.
   Google Scholar